JAMA Cardiology

JAMA Cardiology JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed publications

In symptomatic patients without known coronary disease, -derived plaque burden and volume independently predicted MACE ...
02/11/2026

In symptomatic patients without known coronary disease, -derived plaque burden and volume independently predicted MACE beyond clinical risk and standard imaging findings. https://bit.ly/4aeBTYY

Intensive lipid-lowering therapy and lower on-treatment LDL-C were associated with less neoatherosclerosis and reduced l...
02/11/2026

Intensive lipid-lowering therapy and lower on-treatment LDL-C were associated with less neoatherosclerosis and reduced late stent failure risk after for STEMI.

https://ja.ma/4acsTlQ

đź’¬ Invited Commentary: Flynn et al demonstrate that clonal hematopoiesis of indeterminate potential (CHIP) represents an ...
02/10/2026

đź’¬ Invited Commentary: Flynn et al demonstrate that clonal hematopoiesis of indeterminate potential (CHIP) represents an independent, gene-specific risk factor for incident heart failure (HF), highlighting the need for gene-targeted prevention strategies in cardiovascular care.

https://ja.ma/4tefMci

Clonal hematopoiesis of indeterminate potential (CHIP), especially non-DNMT3A driver gene subtypes, was independently as...
02/09/2026

Clonal hematopoiesis of indeterminate potential (CHIP), especially non-DNMT3A driver gene subtypes, was independently associated with increased risk of incident heart failure (HF).

Mediation analyses indicate CHIP-associated comorbidities such as coronary artery disease, atrial fibrillation, diabetes, and chronic kidney disease explain only a minority of this risk, suggesting direct myocardial effects.

https://ja.ma/4c8C6hq

đź’¬ Editor's Note: Jain et al present a prospective pilot application of an -driven model to identify patients at risk fo...
02/08/2026

💬 Editor's Note: Jain et al present a prospective pilot application of an -driven model to identify patients at risk for amyloid transthyretin cardiomyopathy (ATTR-CM), demonstrating the model’s potential for enhanced detection.

Despite improved predictive value, challenges remain, including limited uptake of diagnostic testing and the need to clarify the impact of earlier detection on patient outcomes and health system costs.

https://bit.ly/4ktKNFu

An model (ATTRACTnet) integrated electrocardiogram data, echo metrics, demographics, and diagnosis codes to support de...
02/07/2026

An model (ATTRACTnet) integrated electrocardiogram data, echo metrics, demographics, and diagnosis codes to support detection of transthyretin amyloid cardiomyopathy (ATTR-CM).

The program identified undiagnosed, high-risk patients, achieving a positive test rate 2.8 times higher than historical controls and an 18% relative increase in new diagnoses over the previous year.

https://ja.ma/3NUfY0h

Among older patients with , abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater abs...
02/06/2026

Among older patients with , abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. https://bit.ly/4bzTTOr

For US adults eligible for secondary prevention, would be cost-effective if annual drug cost is reduced by 18% to $7...
02/05/2026

For US adults eligible for secondary prevention, would be cost-effective if annual drug cost is reduced by 18% to $7055 or if current cash price is widely available.

https://bit.ly/4r2xXAm

đź’¬ Editorial: Price reductions for inhibitors and substantially improved cost-effectiveness and access, highlighting ...
02/04/2026

đź’¬ Editorial: Price reductions for inhibitors and substantially improved cost-effectiveness and access, highlighting the need for value-based drug pricing in cardiovascular care.

https://ja.ma/4atZ0P8

From JAMA: Analysis of NHANES data from 2021 to 2023 found that 79.1% of US adults with had blood pressure above the 2...
02/03/2026

From JAMA: Analysis of NHANES data from 2021 to 2023 found that 79.1% of US adults with had blood pressure above the 2025 American Heart Association/American College of Cardiology goal of

RCT: Among patients with obstructive prosthetic heart valve thrombosis, tenecteplase achieved higher complete thrombolyt...
02/03/2026

RCT: Among patients with obstructive prosthetic heart valve thrombosis, tenecteplase achieved higher complete thrombolytic success (97.5%) than alteplase (81.5%) and a shorter hospital stay.

https://ja.ma/49UGvTT

JAMA Cardiology marks its 10th anniversary with a leadership transition that builds on a decade of extraordinary growth....
02/02/2026

JAMA Cardiology marks its 10th anniversary with a leadership transition that builds on a decade of extraordinary growth.

Today we welcome Barbara Casadei, MD, DPhil, from the National Heart and Lung Institute, Imperial College London, as Editor in Chief. An internationally recognized clinician‑scientist, Dr Casadei brings extensive experience in global cardiovascular research.

In her inaugural Editorial, Dr Casadei outlines a vision focused on:

đź“Ś Make JAMA Cardiology a global meeting place, fostering engagement and contributions from a diverse, international community. The journal will disseminate trustworthy, evidence-based information, especially on managing increasingly older and complex patients, while addressing the challenges posed by misinformation and pressures on the profession.

đź“Ś Encourage innovative scholarship that develops new ways to implement preventive measures for cardiovascular disease at scale, learning from countries that have creatively overcome cultural, financial, or geographic obstacles

đź“Ś Demystify emerging technologies, particularly artificial intelligence (AI), and make them accessible and familiar to the cardiovascular community and narrow the divide between clinicians and data/computer scientists.

“We want to inspire and support the next generation of cardiovascular investigators and hold ourselves responsible for communicating the importance of conducting research that has the potential to improve cardiovascular health and, thus, the quality of life of hundreds of millions of people worldwide,” she writes.

đź”— Read the Editorial: https://ja.ma/3NQN0hQ
📬 Subscribe for updates: https://ja.ma/4a9GZUX
đź’ˇ Submit high impact work: https://ja.ma/4rkktzA

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Cardiology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category